Search Results
Viewing: 4951-4960 of 11641 | All
News
Nationwide Children's Hospital Ranked #1 Hospital in Ohio and in Top 10 among Hospitals in U.S. on Forbes List of “America’s Best Employers”
Nationwide Children’s Hospital has been named one of “America’s Best Employers” by Forbes. Joining 35 hospitals and health systems named to the national list of 500 top large employers (companies with more than 5,000 U.S.-based employees), Nationwide Children’s is the top ranked hospital in Ohio and 9th among all hospitals in the United States.
News
Study supports virotherapy as a potential treatment for brain tumors
A new study provides additional evidence of the efficacy of virotherapy for glioblastoma, the most deadly type of brain tumor. The research findings, published Feb. 1, 2022, in Clinical Cancer Research, indicate that an oncolytic herpes simplex virus, G207, appears to boost immune response and that this is associated with better overall survival for patients with glioblastoma.
News
Behavioral Health Research, Genomics Programs Highlight $10 Million Nationwide Foundation Donation to Nationwide Children’s Hospital
Behavioral health research and genomics are among several programs at Nationwide Children’s Hospital that will continue to benefit from funding as part of a new $10 million gift that the Nationwide Foundation is making through their Pediatric Innovation Fund.
News
New Study Finds Battery-Related Injuries in Children More than Doubled in Recent Decade
Pediatric battery-related emergency department (ED) visits have increased considerably in the last decade, particularly among children 5 years old and under, according to a new study published today in Pediatrics by a team of researchers from Safe Kids Worldwide and Nationwide Children’s Hospital.
News
St. Baldrick's Foundation Funds $8.9 Million in Grants to Support the Most Promising Childhood Cancer Research
No hospital has a monopoly on good ideas. This is why the St. Baldrick's Foundation funds the most promising research — no matter where it takes place – from your backyard institution to other cutting edge research facilities treating childhood cancers around the globe. Since 2005, this philosophy has translated to more than 1,674 grants in 31 countries, totaling more than $322 million. Thanks to the tremendous efforts of volunteers, donors, partners and advocates across the country this past year, St. Baldrick's is proud to announce $8.9 million has been awarded in new grants.
News
Nationwide Children’s Hospital Selected as Clinical Coordinating Center in Large National Clinical Trial Sponsored by National Heart Lung and Blood Institute (NHLBI)
The National Heart Lung and Blood Institute (NHLBI) of the National Institutes of Health (NIH) has announced that Nationwide Children’s Hospital has been selected for funding as the Clinical Coordinating Center for the multicenter randomized trial: “Percutaneous intervention versus observational trial of arterial ductus in lower gestational age infants (PIVOTAL)”.
News
Investigators Develop Technique to Effectively Edit NK Cells to Target Specific Cancer Cells
Originally, NK cells seemed promising for a natural therapy to fight cancer due to their innate ability to recognize any cells expressing stress or signs of infection. But investigators quickly realized they faced three key challenges: first, it was difficult to grow a large enough number of NK cells in the lab to offer useful infusions at a reasonable cost; second, an ideal universal donor solution was needed to make NK cell products faster, more reliably and with off-the-shelf availability; and third, NK cells were resistant to genetic modifications that might help them better target specific types of cancer cells. Nationwide Children’s Hospital investigators and their collaborators painstakingly solved the first two problems over the past decade. Now, they’ve conquered the third.
News
Early Phase Gene Therapy Study for SMARD1/CMT2S Disease Now Enrolling
Nationwide Children's Hospital has launched a new Phase I/IIa gene replacement clinical study to evaluate the safety of a gene therapy for IGHMBP2-related diseases, specifically spinal muscular atrophy with respiratory distress type 1 (SMARD1) and Charcot Marie Tooth disease type 2S (CMT2S). SMARD1 and CMT2S are rare inherited conditions that are both caused by mutations in the IGHMBP2 gene, of which more than 60 have been found to date. SMARD1 is the most severe form of these diseases and causes muscle weakness and respiratory failure in infancy.
News
Nationwide Children’s Hospital Columbus Marathon & 1/2 Marathon Announce 2022 Patient Champions
The Nationwide Children’s Hospital Columbus Marathon & 1/2 Marathon is pleased to announce the 2022 “Patient Champions” who will represent 24 of the 26 miles on the course. The other two miles, the Encore Mile, will honor former Marathon Patient Champions, and the Angel Mile, will celebrate the lives of those who are no longer with us.
News
Catherine Krawczeski, MD, Named Chief of the Department of Pediatrics at Nationwide Children’s Hospital
Catherine Dent Krawczeski, MD, has been named Physician-in-Chief and Chief of the Department of Pediatrics at Nationwide Children’s Hospital. Dr. Krawczeski will also serve as Chair of Pediatrics at The Ohio State University College of Medicine, pending approval from The Ohio State University Board of Trustees. Dr. Krawczeski will begin this new role in Summer 2022.